Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RHB-104 · 2 trials · 2 indications
Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.
| Arm | Type | Description |
|---|---|---|
| RHB-104 | ACTIVE_COMPARATOR | 5 RHB-104 capsules administered orally BID |
| Placebo | PLACEBO_COMPARATOR | 5 placebo capsules administered orally BID |
| Name | Type | Description |
|---|---|---|
| RHB-104 | DRUG | 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine |
| Placebo | DRUG | 5 placebo capsules administered orally BID |
Inclusion Criteria 1. Signed fully informed consent provided as per this protocol. 2. Diagnosis of Crohn's Disease confirmed by endoscopy or radiography and/or histology at least 6 months prior to randomization into the study. 3. CD involving the ileum and/or colon 4. Moderately to severely active ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 17 | PHASE3 | Vedolizumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |